ClinicalTrials.gg
Not yet recruitingNCT07732686Updated Nov 18, 2026

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

An observational study in Pancreas Cancer, Hepatocellular Carcinoma and Lung Cancer, sponsored by University of Oklahoma. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Oklahoma · Observational

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
27th of 230
2,000 · median 137
Started
2026
with 82 others
Observational
231 of 1,850
70 open now
Primary completion
2027-11
later than 268 of 468 live
Registered
1,826th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 27th largest by planned enrollment of the 230 observational ones that give a count, is one of 83 that started in 2026, is one of 231 observational ones, reaches primary completion later than 268 of the 468 other live ones, and was the 1,826th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.

Read the detailed description

This study aims to determine whether metabolic changes associated with cancer produce distinct alterations in exhaled breath compared with those of healthy individuals. Breath samples will be analyzed using machine learning techniques to identify volatile organic compound (VOC) patterns and develop diagnostic algorithms capable of detecting multiple types of cancer. The long-term goal is to establish a noninvasive, breath-based screening tool that can facilitate the early detection of various cancers.

Additionally, patients and healthy participants who consent to this study may opt in to be contacted in the future to provide additional breath samples.

03

Conditions studied

  • Pancreas Cancer
  • Hepatocellular Carcinoma
  • Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Colon Cancer
  • Bladder Cancer
  • Other Cancer

Keywords

  • VOC
  • PTR-MS
  • ML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients diagnosed with malignancies and healthy individuals who meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 at the time of consent. Male and female patients to be tested.
  • Capable of understanding written and/or spoken English language.
  • Able to provide .
  • Cancer of any type.
  • Newly diagnosed cancer and untreated or established diagnosis of cancer. For established cancer patients, no active anti-cancer treatment for more than one month (reasons for no treatment are such as relapse, progression of cancer, , or intolerance to treatment etc.)

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18.
  • Anticipated inability to complete breath sampling procedure.
  • Unable to provide .
  • Pregnant women
  • Active respiratory infection symptoms
  • Recent use of antibiotics
  • Difficulty in performing coached exhalation
  • Individuals who are unable to follow the instructions
  • Cancer patients who are on active treatment for cancer or have received cancer treatment within one month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diagnosed Malignancies

    Participants in this group either have a newly diagnosed, untreated cancer or a pre-existing cancer diagnosis but are not currently receiving anticancer therapy. Participants with a pre-existing diagnosis must not have received any anticancer treatment within the previous month.

    Device: Proton Transfer Reaction Mass Spectrometry Analysis

  • Healthy Control Group

    Participants in this control group have no current or prior diagnosis of a malignancy.

    Device: Proton Transfer Reaction Mass Spectrometry Analysis

Interventions

  • DeviceProton Transfer Reaction Mass Spectrometry Analysis

    This is a noninvasive intervention. Participants will be asked to provide a breath sample using a disposable mouthpiece equipped with a saliva/moisture trap and a non-rebreathing valve. Breath samples will be collected through normal, steady exhalation. The entire breath collection process is expected to take no more than 30 minutes to complete.

    Also known as: PTR-MS

06

What researchers measure

Primary outcomes

  1. VOC Signature Collection.

    The successful collection of breath samples from 1000 cancer patients and 1000 healthy volunteers.

    Time frame: 2 Years

  2. Assess the sensitivity of Machine Learning (ML) Algorithm In The Test Dataset.

    Using the training dataset, qualitative output generated by the PTR-MS instrument will be analyzed using machine learning methods to identify volatile organic compound (VOC) patterns associated with different cancer types, including pancreatic, esophageal, hepatocellular carcinoma, lung, and ovarian cancers. The trained machine learning model will be tested using the dataset.

    Time frame: 1 Years

Secondary outcomes

  1. Assess The Specificity and Accuracy of ML Analysis In The Test Dataset.

    To determine the specificity, and overall diagnostic accuracy of the machine learning (ML) algorithm for detecting pancreatic, esophageal, hepatocellular carcinoma, lung, and ovarian cancers within the test dataset.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 12 months is below that.

Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2026 → Nov 2026, primary completion Oct 2027 → Nov 2027 and completion Oct 2029 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Nov 2027was Oct 2027
CompletionEst.
Nov 2029was Oct 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 18, 2026
Primary completion
Oct 2027→Nov 2027
Nov 18, 2026
Study completion
Oct 2029→Nov 2029
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 2026→Nov 2026
    Primary completion Oct 2027→Nov 2027
    Study completion Oct 2029→Nov 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07732686
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Lead Onco Nurse
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Nirmal Choradia, MD
Contact
Nirmal-Choradia@ouhsc.edu
Nirmal Choradia, MD
principal investigator · University of Oklahoma - Stephenson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion